Business
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show that HER-096 modulates Parkinson’s disease-relevant pathways, consistent with preclinical data, and supporting further clinical developmentHER-096 exposure was associated with changes across key disease-related pathways, including proteostasis, mitochondrial function, and neuroinflammation,
About this update from Herantis Pharma Plc
[{"type":"image","alt":"Herantis Pharma plc","displaySize":"","headline":null,"caption":"Herantis Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TztkX3djp9fmQ02UkZu7vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646","width":300,"height":51}},"lazy":false},{"type":"text","content":"Herantis Pharma Plc – Company release","length":37,"tagName":"p"},{"type":"text","content":"Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease","length":154,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Biomarker data show that HER-096 modulates Parkinson’s disease-relevant pathways, consistent with preclinical data, and supporting further clinical development","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"HER-096 exposure was associated with changes across key disease-related pathways, including proteostasis, mitochondrial function, and neuroinflammation, aligned with the expected mechanism of action and indicating disease-modifying potential","length":241,"tagName":"p"}]},{"val":[{"type":"text","content":"Herantis will hold a webcast tomorrow, January 8th at 12:00 EET (11:00 CET). ","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":476,"olType":false},{"type":"text","content":"Link to the webcast: https://herantis.videosync.fi/phase-1b-biomarker-data","length":74,"tagName":"p"},{"type":"text","content":"Espoo, Finland, 7 January 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces biomarker data from its Phase 1b trial of HER-096. The results show clear clinical evidence of biological response to HER-096 exposure in people with Parkinson’s disease, with a biomarker profile consistent with the expected mechanism of action of HER-096.","length":450,"tagName":"p"},{"type":"text","content":"“Biomarker evidence supporting the expected mechanism of action of HER-096 in people with Parkinson’s disease marks a key development mileston...